The Sphingosine Kinase 2 Inhibitor Opaganib Protects Against Acute Kidney Injury in Mice

References

• Lagny MG, Jouret F, Koch JN, et al. Incidence and outcomes of acute kidney injury after cardiac surgery using either criteria of the RIFLE classification. BMC Nephrol. 2015;16:76. doi:10.1186/s12882-015-0066-9
   PubMed Web of Science ®Google Scholar
• Boldt J, Brenner T, Lehmann A, Suttner SW, Kumle B, Isgro F. Is kidney function altered by the duration of cardiopulmonary bypass? Ann Thorac Surg. 2003;75(3):906–912. doi:10.1016/S0003-4975(02)04559-9
   PubMed Web of Science ®Google Scholar
• Rosner MH, Okusa MD. Acute kidney injury associated with cardiac surgery. Clin J Am Soc Nephrol. 2006;1(1):19–32. doi:10.2215/CJN.00240605
   PubMed Web of Science ®Google Scholar
• Chin J, Palop JJ, Puolivali J, et al. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer’s disease. J Neurosci. 2005;25(42):9694–9703. doi:10.1523/JNEUROSCI.2980-05.2005
   PubMed Web of Science ®Google Scholar
• Koo DD, Welsh KI, Roake JA, Morris PJ, Fuggle SV. Ischemia/reperfusion injury in human kidney transplantation: an immunohistochemical analysis of changes after reperfusion. Am J Pathol. 1998;153(2):557–566. doi:10.1016/S0002-9440(10)65598-8
   PubMed Web of Science ®Google Scholar
• Menez S, Parikh CR. Overview of acute kidney manifestations and management of patients with COVID-19. Am J Physiol. 2021;321(4):F403–F410.
   Google Scholar
• Gomez-Larrauri A, Presa N, Dominguez-Herrera A, Ouro A, Trueba M, Gomez-Munoz A. Role of bioactive sphingolipids in physiology and pathology. Essays Biochem. 2020;64(3):579–589. doi:10.1042/EBC20190091
   PubMed Web of Science ®Google Scholar
• Hu Y, Dai K. Sphingosine 1-phosphate metabolism and signaling. Adv Exp Med Biol. 2022;1372:67–76.
   PubMedGoogle Scholar
• Ziegler AC, Muller T, Graler MH. Sphingosine 1-phosphate in sepsis and beyond: its role in disease tolerance and host defense and the impact of carrier molecules. Cell Signal. 2021;78:109849. doi:10.1016/j.cellsig.2020.109849
   PubMed Web of Science ®Google Scholar
• Abou Daher A, El Jalkh T, Eid AA, Fornoni A, Marples B, Zeidan YH. Translational aspects of sphingolipid metabolism in renal disorders. Int J Mol Sci. 2017;18(12):2528. doi:10.3390/ijms18122528
   PubMed Web of Science ®Google Scholar
• Dupre TV, Siskind LJ. The role of sphingolipids in acute kidney injury. Adv Biol Regul. 2018;70:31–39. doi:10.1016/j.jbior.2018.11.003
   PubMedGoogle Scholar
• Ueda N. A rheostat of ceramide and sphingosine-1-phosphate as a determinant of oxidative stress-mediated kidney injury. Int J Mol Sci. 2022;23(7):4010. doi:10.3390/ijms23074010
   PubMed Web of Science ®Google Scholar
• French KJ, Zhuang Y, Maines LW, et al. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J Pharmacol Exp Ther. 2010;333(1):129–139. doi:10.1124/jpet.109.163444
   PubMed Web of Science ®Google Scholar
• Gao P, Peterson YK, Smith RA, Smith CD. Characterization of isoenzyme-selective inhibitors of human sphingosine kinases. PLoS One. 2012;7(9):e44543. doi:10.1371/journal.pone.0044543
   PubMed Web of Science ®Google Scholar
• Beljanski V, Knaak C, Smith CD. A novel sphingosine kinase inhibitor induces autophagy in tumor cells. J Pharmacol Exp Ther. 2010;333(2):454–464. doi:10.1124/jpet.109.163337
   PubMed Web of Science ®Google Scholar
• Antoon JW, White MD, Slaughter EM, et al. Targeting NFkB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer Biol Ther. 2011;11(7):678–689. doi:10.4161/cbt.11.7.14903
   PubMed Web of Science ®Google Scholar
• Schrecengost RS, Keller SN, Schiewer MJ, Knudsen KE, Smith CD. Downregulation of critical oncogenes by the selective SK2 inhibitor ABC294640 hinders prostate cancer progression. Mol Cancer Res. 2015;13(12):1591–1601. doi:10.1158/1541-7786.MCR-14-0626
   PubMed Web of Science ®Google Scholar
• Venant H, Rahmaniyan M, Jones EE, et al. The sphingosine kinase 2 inhibitor ABC294640 reduces the growth of prostate cancer cells and results in accumulation of dihydroceramides in vitro and in vivo. Mol Cancer Ther. 2015;14(12):2744–2752. doi:10.1158/1535-7163.MCT-15-0279
   PubMed Web of Science ®Google Scholar
• Venkata JK, An N, Stuart R, et al. Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma. Blood. 2014;124(12):1915–1925. doi:10.1182/blood-2014-03-559385
   PubMed Web of Science ®Google Scholar
• Lewis CS, Voelkel-Johnson C, Smith CD. Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640. Oncotarget. 2016;7(37):60181–60192. doi:10.18632/oncotarget.11112
   PubMedGoogle Scholar
• Antoon JW, White MD, Meacham WD, et al. Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640. Endocrinology. 2010;151(11):5124–5135. doi:10.1210/en.2010-0420
   PubMed Web of Science ®Google Scholar
• Beljanski V, Knaak C, Zhuang Y, Smith CD. Combined anticancer effects of sphingosine kinase inhibitors and sorafenib. Invest New Drugs. 2011;29(6):1132–1142. doi:10.1007/s10637-010-9452-0
   PubMed Web of Science ®Google Scholar
• Beljanski V, Lewis CS, Smith CD. Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts. Cancer Biol Ther. 2011;11(5):524–534. doi:10.4161/cbt.11.5.14677
   PubMed Web of Science ®Google Scholar
• Qin Z, Dai L, Trillo-Tinoco J, et al. Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma. Mol Cancer Ther. 2014;13(1):154–164. doi:10.1158/1535-7163.MCT-13-0466
   PubMed Web of Science ®Google Scholar
• Xun C, Chen MB, Qi L, et al. Targeting sphingosine kinase 2 (SphK2) by ABC294640 inhibits colorectal cancer cell growth in vitro and in vivo. J Exp Clin Cancer Res. 2015;34:94. doi:10.1186/s13046-015-0205-y
   PubMed Web of Science ®Google Scholar
• Fitzpatrick LR, Green CL, Maines LW, Smith CD. Experimental osteoarthritis in rats is attenuated by ABC294640, a selective inhibitor of sphingosine kinase-2. Pharmacology. 2011;87:135–143. doi:10.1159/000323911
   PubMed Web of Science ®Google Scholar
• Fitzpatrick LR, Green CL, Frauenhoffer EE, et al. Attenuation of arthritis in rodents by a novel orally-available inhibitor of sphingosine kinase. Inflammopharmacology. 2010;19:75–87. doi:10.1007/s10787-010-0060-6
   PubMedGoogle Scholar
• Maines LW, Fitzpatrick LR, French KJ, et al. Suppression of ulcerative colitis in mice by orally available inhibitors of sphingosine kinase. Dig Dis Sci. 2008;53(4):997–1012. doi:10.1007/s10620-007-0133-6
   PubMed Web of Science ®Google Scholar
• Maines LW, Fitzpatrick LR, Green CL, Zhuang Y, Smith CD. Efficacy of a novel sphingosine kinase inhibitor in experimental Crohn’s disease. Inflammopharmacology. 2010;18(2):73–85. doi:10.1007/s10787-010-0032-x
   PubMedGoogle Scholar
• Maines LW, French KJ, Wolpert EB, Antonetti DA, Smith CD. Pharmacologic manipulation of sphingosine kinase in retinal endothelial cells: implications for angiogenic ocular diseases. Invest Ophthalmol Vis Sci. 2006;47(11):5022–5031. doi:10.1167/iovs.05-1236
   PubMed Web of Science ®Google Scholar
• Britten CD, Garrett-Mayer E, Chin SH, et al. A phase I study of ABC294640, a first-in-class sphingosine kinase-2 inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2017;23(16):4642–4650. doi:10.1158/1078-0432.CCR-16-2363
   PubMed Web of Science ®Google Scholar
• Smith CD, Maines LW, Keller SN, et al. Recent progress in the development of opaganib for the treatment of Covid-19. Drug Des Devel Ther. 2022;16:2199–2211. doi:10.2147/DDDT.S367612
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Skolnick AW, Rafiq AM, et al. Opaganib in COVID-19 pneumonia: results of a randomized, placebo-controlled Phase 2a trial. Open Forum Infect Dis. 2022;9:ofac232. doi:10.1093/ofid/ofac232
   PubMedGoogle Scholar
• Wei Q, Dong Z. Mouse model of ischemic acute kidney injury: technical notes and tricks. Am J Physiol. 2012;303(11):F1487–1494. doi:10.1152/ajprenal.00352.2012
   PubMed Web of Science ®Google Scholar
• Pabla N, Scindia Y, Gigliotti J, Bajwa A. Mouse models of acute kidney injury. In: Purevjav E, editor. Preclinical Animal Modeling in Medicine. IntechOpen; 2022:1–19.
   Google Scholar
• Fitzpatrick LR, Wang J, Le T. In vitro and in vivo effects of gliotoxin, a fungal metabolite: efficacy against dextran sodium sulfate-induced colitis in rats. Dig Dis Sci. 2000;45(12):2327–2336. doi:10.1023/A:1005630723111
   PubMed Web of Science ®Google Scholar
• Pyne NJ, Adams DR, Pyne S. Sphingosine kinase 2 in autoimmune/inflammatory disease and the development of sphingosine kinase 2 inhibitors. Trends Pharmacol Sci. 2017;38(7):581–591. doi:10.1016/j.tips.2017.04.003
   PubMed Web of Science ®Google Scholar
• Xia P, Gamble JR, Rye KA, et al. Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase pathway. Proc Natl Acad Sci U S A. 1998;95(24):14196–14201. doi:10.1073/pnas.95.24.14196
   PubMed Web of Science ®Google Scholar
• Igarashi J, Bernier SG, Michel T. Sphingosine 1-phosphate and activation of endothelial nitric-oxide synthase. differential regulation of Akt and MAP kinase pathways by EDG and bradykinin receptors in vascular endothelial cells. J Biol Chem. 2001;276(15):12420–12426. doi:10.1074/jbc.M008375200
   PubMed Web of Science ®Google Scholar
• Igarashi J, Michel T. Sphingosine 1-phosphate and isoform-specific activation of phosphoinositide 3-kinase beta. Evidence for divergence and convergence of receptor-regulated endothelial nitric-oxide synthase signaling pathways. J Biol Chem. 2001;276(39):36281–36288. doi:10.1074/jbc.M105628200
   PubMed Web of Science ®Google Scholar
• Pettus BJ, Bielawski J, Porcelli AM, et al. The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-alpha. FASEB J. 2003;17(11):1411–1421. doi:10.1096/fj.02-1038com
   PubMed Web of Science ®Google Scholar
• Kruidenier L, Kuiper I, Lamers CB, Verspaget HW. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants. J Pathol. 2003;201(1):28–36. doi:10.1002/path.1409
   PubMed Web of Science ®Google Scholar
• Itagaki K, Hauser CJ. Sphingosine 1-phosphate, a diffusible calcium influx factor mediating store-operated calcium entry. J Biol Chem. 2003;278(30):27540–27547. doi:10.1074/jbc.M301763200
   PubMed Web of Science ®Google Scholar
• MacKinnon AC, Buckley A, Chilvers ER, Rossi AG, Haslett C, Sethi T. Sphingosine kinase: a point of convergence in the action of diverse neutrophil priming agents. J Immunol. 2002;169(11):6394–6400. doi:10.4049/jimmunol.169.11.6394
   PubMed Web of Science ®Google Scholar
• Stepanovska B, Huwiler A. Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases. Pharmacol Res. 2020;154:104170. doi:10.1016/j.phrs.2019.02.009
   PubMed Web of Science ®Google Scholar
• Sukocheva OA, Furuya H, Ng ML, et al. Sphingosine kinase and sphingosine-1-phosphate receptor signaling pathway in inflammatory gastrointestinal disease and cancers: a novel therapeutic target. Pharmacol Ther. 2020;207:107464. doi:10.1016/j.pharmthera.2019.107464
   PubMed Web of Science ®Google Scholar
• Wang J, Goren I, Yang B, et al. Review article: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis - a unique therapeutic target in inflammatory bowel disease. Aliment Pharmacol Ther. 2022;55(3):277–291. doi:10.1111/apt.16741
   PubMed Web of Science ®Google Scholar
• Zhang X, Ritter JK, Li N. Sphingosine-1-phosphate pathway in renal fibrosis. Am J Physiol. 2018;315(4):F752–F756. doi:10.1152/ajprenal.00596.2017
   Web of Science ®Google Scholar
• Bajwa A, Rosin DL, Chroscicki P, et al. Sphingosine 1-phosphate receptor-1 enhances mitochondrial function and reduces cisplatin-induced tubule injury. J Am Soc Nephrol. 2015;26(4):908–925. doi:10.1681/ASN.2013121351
   PubMed Web of Science ®Google Scholar
• Dupre TV, Doll MA, Shah PP, et al. Inhibiting glucosylceramide synthase exacerbates cisplatin-induced acute kidney injury. J Lipid Res. 2017;58(7):1439–1452. doi:10.1194/jlr.M076745
   PubMed Web of Science ®Google Scholar
• Sears SM, Dupre TV, Shah PP, et al. Neutral ceramidase deficiency protects against cisplatin-induced acute kidney injury. J Lipid Res. 2022;63(3):100179. doi:10.1016/j.jlr.2022.100179
   PubMed Web of Science ®Google Scholar
• Zager RA, Iwata M, Conrad DS, Burkhart KM, Igarashi Y. Altered ceramide and sphingosine expression during the induction phase of ischemic acute renal failure. Kidney Int. 1997;52(1):60–70. doi:10.1038/ki.1997.304
   PubMed Web of Science ®Google Scholar
• Jo SK, Bajwa A, Ye H, et al. Divergent roles of sphingosine kinases in kidney ischemia-reperfusion injury. Kidney Int. 2008;75:167–175.
   PubMed Web of Science ®Google Scholar
• Gon Y, Wood MR, Kiosses WB, et al. S1P3 receptor-induced reorganization of epithelial tight junctions compromises lung barrier integrity and is potentiated by TNF. Proc Natl Acad Sci U S A. 2005;102(26):9270–9275. doi:10.1073/pnas.0501997102
   PubMed Web of Science ®Google Scholar
• Fuller TF, Hoff U, Kong L, et al. Cytoprotective actions of FTY720 modulate severe preservation reperfusion injury in RatRenal transplants. Transplantation. 2010;89(4):402–408. doi:10.1097/TP.0b013e3181caa499
   PubMed Web of Science ®Google Scholar
• Kaudel CP, Schmiddem U, Frink M, et al. FTY720 for treatment of ischemia-reperfusion injury following complete renal ischemia in C57/BL6 mice. Transplant Proc. 2006;38(3):679–681. doi:10.1016/j.transproceed.2006.01.033
   PubMed Web of Science ®Google Scholar
• Claus RA, Bunck AC, Bockmeyer CL, et al. Role of increased sphingomyelinase activity in apoptosis and organ failure of patients with severe sepsis. FASEB J. 2005;19(12):1719–1721. doi:10.1096/fj.04-2842fje
   PubMed Web of Science ®Google Scholar
• Drobnik W, Liebisch G, Audebert FX, et al. Plasma ceramide and lysophosphatidylcholine inversely correlate with mortality in sepsis patients. J Lipid Res. 2003;44(4):754–761. doi:10.1194/jlr.M200401-JLR200
   PubMed Web of Science ®Google Scholar
• Graler MH. The role of sphingosine 1-phosphate in immunity and sepsis. Am J Clin Exp Immunol. 2012;1(2):90–100.
   PubMedGoogle Scholar
• Haimovitz-Friedman A, Cordon-Cardo C, Bayoumy S, et al. Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation. J Exp Med. 1997;186(11):1831–1841. doi:10.1084/jem.186.11.1831
   PubMed Web of Science ®Google Scholar
• Lo CJ, Fu M, Lo FR, Cryer HG. Macrophage TNF mRNA expression induced by LPS is regulated by sphingomyelin metabolites. Shock. 1999;11(6):411–415.
   PubMed Web of Science ®Google Scholar
• Peng H, Li C, Kadow S, et al. Acid sphingomyelinase inhibition protects mice from lung edema and lethal Staphylococcus aureus sepsis. J Mol Med. 2015;93(6):675–689. doi:10.1007/s00109-014-1246-y
   PubMed Web of Science ®Google Scholar
• Smith CD, Berk SG, Brandl MT, Riley LW. Survival characteristics of diarrheagenic Escherichia coli pathotypes and Helicobacter pylori during passage through the free-living ciliate, Tetrahymena sp. FEMS Microbiol Ecol. 2012;82(3):574–583. doi:10.1111/j.1574-6941.2012.01428.x
   PubMed Web of Science ®Google Scholar
• Liu Q, Rehman H, Shi Y, et al. Inhibition of sphingosine kinase-2 suppresses inflammation and attenuates graft injury after liver transplantation in rats. PLoS One. 2012;7(7):e41834. doi:10.1371/journal.pone.0041834
   PubMed Web of Science ®Google Scholar
• Ebenezer DL, Berdyshev EV, Bronova IA, et al. Pseudomonas aeruginosa stimulates nuclear sphingosine-1-phosphate generation and epigenetic regulation of lung inflammatory injury. Thorax. 2019;74(6):579–591. doi:10.1136/thoraxjnl-2018-212378
   PubMed Web of Science ®Google Scholar
• Yang G, Gu M, Chen W, et al. SPHK-2 promotes the particle-induced inflammation of RAW264.7 by maintaining consistent expression of TNF-alpha and IL-6. Inflammation. 2018;41(4):1498–1507. doi:10.1007/s10753-018-0795-6
   PubMed Web of Science ®Google Scholar
• Zhu X, Shi D, Cao K, et al. Sphingosine kinase 2 cooperating with Fyn promotes kidney fibroblast activation and fibrosis via STAT3 and AKT. Biochim Biophys Acta. 2018;1864(11):3824–3836. doi:10.1016/j.bbadis.2018.09.007
   Web of Science ®Google Scholar
• Kim IY, Park YK, Song SH, et al. Akt1 is involved in tubular apoptosis and inflammatory response during renal ischemia-reperfusion injury. Mol Biol Rep. 2020;47(12):9511–9520. doi:10.1007/s11033-020-06021-1
   PubMed Web of Science ®Google Scholar
• Sang Z, Dong S, Zhang P, Wei Y. miR214 ameliorates sepsis-induced acute kidney injury via PTEN/AKT/mTORregulated autophagy. Mol Med Rep. 2021;24(4). doi:10.3892/mmr.2021.12322
   PubMed Web of Science ®Google Scholar
• Wang H, Wang Y, Wang X, et al. PTEN alleviates maladaptive repair of renal tubular epithelial cells by restoring CHMP2A-mediated phagosome closure. Cell Death Dis. 2021;12(12):1087. doi:10.1038/s41419-021-04372-6
   PubMed Web of Science ®Google Scholar
• Zhan Y, Zhu M, Liu S, et al. MicroRNA93 inhibits the apoptosis and inflammatory response of tubular epithelial cells via the PTEN/AKT/mTOR pathway in acute kidney injury. Mol Med Rep. 2021;24(3). doi:10.3892/mmr.2021.12305
   Web of Science ®Google Scholar
• Somanath PR. Is targeting Akt a viable option to treat advanced-stage COVID-19 patients? Am J Physiol. 2020;319(1):L45–L47. doi:10.1152/ajplung.00124.2020
   Web of Science ®Google Scholar
• Hultstrom M, Becirovic-Agic M, Jonsson S. Comparison of acute kidney injury of different etiology reveals in-common mechanisms of tissue damage. Physiol Genomics. 2018;50(3):127–141. doi:10.1152/physiolgenomics.00037.2017
   PubMed Web of Science ®Google Scholar
• Liu D, Liu Y, Zheng X, Liu N. c-MYC-induced long noncoding RNA MEG3 aggravates kidney ischemia-reperfusion injury through activating mitophagy by upregulation of RTKN to trigger the Wnt/beta-catenin pathway. Cell Death Dis. 2021;12(2):191. doi:10.1038/s41419-021-03466-5
   PubMed Web of Science ®Google Scholar
• Xu D, Wang B, Chen PP, et al. c-Myc promotes tubular cell apoptosis in ischemia-reperfusion-induced renal injury by negatively regulating c-FLIP and enhancing FasL/Fas-mediated apoptosis pathway. Acta Pharmacol Sin. 2019;40(8):1058–1066. doi:10.1038/s41401-018-0201-9
   PubMed Web of Science ®Google Scholar
• Introna M, Hamilton TA, Kaufman RE, Adams DO, Bast RC. Treatment of murine peritoneal macrophages with bacterial lipopolysaccharide alters expression of c-fos and c-myc oncogenes. J Immunol. 1986;137(8):2711–2715.
   PubMed Web of Science ®Google Scholar
• Yao D, Dong Q, Tian Y, Dai C, Wu S. Lipopolysaccharide stimulates endogenous beta-glucuronidase via PKC/NF-kappaB/c-myc signaling cascade: a possible factor in hepatolithiasis formation. Mol Cell Biochem. 2018;444(1–2):93–102. doi:10.1007/s11010-017-3234-3
   PubMed Web of Science ®Google Scholar
• Zhang Y, Huang T, Jiang L, et al. MCP-induced protein 1 attenuates sepsis-induced acute lung injury by modulating macrophage polarization via the JNK/c-Myc pathway. Int Immunopharmacol. 2019;75:105741. doi:10.1016/j.intimp.2019.105741
   PubMed Web of Science ®Google Scholar
• Li B, Zhao Y, Song M, et al. Role of c-Myc/chloride intracellular channel 4 pathway in lipopolysaccharide-induced neurodegenerative diseases. Toxicology. 2020;429:152312. doi:10.1016/j.tox.2019.152312
   PubMed Web of Science ®Google Scholar
• Song K, Dai L, Long X, Cui X, Liu Y, Di W. Sphingosine kinase 2 inhibitor ABC294640 displays anti-epithelial ovarian cancer activities in vitro and in vivo. Onco Targets Ther. 2019;12:4437–4449. doi:10.2147/OTT.S208519
   PubMed Web of Science ®Google Scholar
• Sundaramoorthy P, Gasparetto C, Kang Y. The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl-2 inhibitor (ABT-199) displays synergistic anti-myeloma effects in myeloma cells without a t(11;14) translocation. Cancer Med. 2018;7:3257–3268. doi:10.1002/cam4.1543
   PubMed Web of Science ®Google Scholar
• Lewis CS, Voelkel-Johnson C, Smith CD. Targeting sphingosine kinases for the treatment of cancer. Adv Cancer Res. 2018;140:295–325.
   PubMed Web of Science ®Google Scholar
• Bhatia D, Choi ME. Autophagy in kidney disease: advances and therapeutic potential. Prog Mol Biol Transl Sci. 2020;172:107–133.
   PubMed Web of Science ®Google Scholar
• Cui J, Bai X, Chen X. Autophagy and acute kidney injury. Adv Exp Med Biol. 2020;1207:469–480.
   PubMed Web of Science ®Google Scholar
• Duann P, Lianos EA, Ma J, Lin PH. Autophagy, innate immunity and tissue repair in acute kidney injury. Int J Mol Sci. 2016;17(5):662. doi:10.3390/ijms17050662
   PubMed Web of Science ®Google Scholar
• Gong L, Pan Q, Yang N. Autophagy and inflammation regulation in acute kidney injury. Front Physiol. 2020;11:576463. doi:10.3389/fphys.2020.576463
   PubMed Web of Science ®Google Scholar
• Casasampere M, Ordonez YF, Casas J, Fabrias G. Dihydroceramide desaturase inhibitors induce autophagy via dihydroceramide-dependent and independent mechanisms. Biochim Biophys Acta. 2017;1861(2):264–275. doi:10.1016/j.bbagen.2016.11.033
   Web of Science ®Google Scholar
• Gagliostro V, Casas J, Caretti A, et al. Dihydroceramide delays cell cycle G1/S transition via activation of ER stress and induction of autophagy. Int J Biochem Cell Biol. 2012;44(12):2135–2143. doi:10.1016/j.biocel.2012.08.025
   PubMed Web of Science ®Google Scholar
• Hernandez-Tiedra S, Fabrias G, Davila D, et al. Dihydroceramide accumulation mediates cytotoxic autophagy of cancer cells via autolysosome destabilization. Autophagy. 2016;12(11):2213–2229. doi:10.1080/15548627.2016.1213927
   PubMed Web of Science ®Google Scholar
• Lee AY, Lee JW, Kim JE, et al. Dihydroceramide is a key metabolite that regulates autophagy and promotes fibrosis in hepatic steatosis model. Biochem Biophys Res Commun. 2017;494(3–4):460–469. doi:10.1016/j.bbrc.2017.10.110
   PubMed Web of Science ®Google Scholar
• Munoz-Guardiola P, Casas J, Megias-Roda E, et al. The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells. Autophagy. 2021;17(6):1349–1366. doi:10.1080/15548627.2020.1761651
   PubMed Web of Science ®Google Scholar
• Signorelli P, Munoz-Olaya JM, Gagliostro V, Casas J, Ghidoni R, Fabrias G. Dihydroceramide intracellular increase in response to resveratrol treatment mediates autophagy in gastric cancer cells. Cancer Lett. 2009;282(2):238–243. doi:10.1016/j.canlet.2009.03.020
   PubMed Web of Science ®Google Scholar
• Wu CY, Jhang JG, Lin WS, et al. Dihydroceramide desaturase promotes the formation of intraluminal vesicles and inhibits autophagy to increase exosome production. iScience. 2021;24(12):103437. doi:10.1016/j.isci.2021.103437
   PubMed Web of Science ®Google Scholar
• McNaughton M, Pitman M, Pitson SM, Pyne NJ, Pyne S. Proteasomal degradation of sphingosine kinase 1 and inhibition of dihydroceramide desaturase by the sphingosine kinase inhibitors, SKi or ABC294640, induces growth arrest in androgen-independent LNCaP-AI prostate cancer cells. Oncotarget. 2016;7(13):16663–16675. doi:10.18632/oncotarget.7693
   PubMedGoogle Scholar
• Shin SH, Kim HY, Yoon HS, et al. A novel selective sphingosine kinase 2 inhibitor, HWG-35D, ameliorates the severity of imiquimod-induced psoriasis model by blocking Th17 differentiation of naive CD4 T lymphocytes. Int J Mol Sci. 2020;21(21):8371. doi:10.3390/ijms21218371
   PubMed Web of Science ®Google Scholar
• Dai L, Bai A, Smith CD, Rodriguez PC, Yu F, Qin Z. ABC294640, a novel sphingosine kinase 2 inhibitor, induces oncogenic virus-infected cell autophagic death and represses tumor growth. Mol Cancer Ther. 2017;16(12):2724–2734. doi:10.1158/1535-7163.MCT-17-0485
   PubMed Web of Science ®Google Scholar
• Ding X, Chaiteerakij R, Moser CD, et al. Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells. Oncotarget. 2016;7(15):20080–20092. doi:10.18632/oncotarget.7914
   PubMedGoogle Scholar